← Solid Biosciences Inc. (SLDB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Solid Biosciences Inc. (SLDB)
Biological Products, (No Diagnostic Substances) · market cap $895M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Solid Biosciences (SLDB) is a ~100-person biotech with a single clinical-stage asset, SGT-003, currently in Phase 3 for Duchenne Muscular Dystrophy (DMD). The company carries a $858M market cap, $297M in net cash (~19 months runway), and no meaningful revenue, having burned roughly $140M in R&D in fiscal 2025 alone.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SGT-003 | Phase 3 | Duchenne Muscular Dystrophy |
| genexolPM + cisplatin | Phase 2 | Locally Advanced Head and Neck Squamous Cell Carcinoma |
| trofosfamide, idarubicin, etoposide | Phase 3 | Soft Tissue Sarcoma |
| Cetuximab | Phase 2 | Head and Neck Neoplasm |
Price & technical context
3-month
-29.1%
6-month
+0.4%
12-month
+21.1%
52-wk range
$3.93–$11.15
vs 50-day MA
-17.8%
vs 200-day MA
-4.6%
Realized vol
78.0%
Max drawdown
-70.4%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SLDB (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.